Item 1.02. Termination of a Material Definitive Agreement.

On April 6, 2021, Johnson & Johnson Enterprise Innovation, Inc ("JJEI") notified Pulmatrix, Inc. (the "Company") that it is terminating the License, Development and Commercialization Agreement (the "Agreement") dated December 26, 2019, by and between JJEI and the Company for the development of PUR1800, the Company's inhaled iSPERSE drug delivery system as formulated with a kinase inhibitor compound. Under the terms of the Agreement, JJEI is entitled to terminate the Agreement for any reason upon ninety (90) days prior written notice. The termination of the Agreement will be effective July 6, 2021.

Item 7.01. Regulation FD Disclosure.

Pulmatrix, Inc. (the "Company") intends, from time to time, to present and/or distribute to the investment community and utilize at various industry and other conferences a slide presentation, which is attached hereto as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.




Item 8.01. Other Events.

The Company issued a press release regarding the termination of the Agreement on April 12, 2021, which is attached hereto as Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits



Exhibit
Number    Description

 99.1       Investor Presentation, dated April 2021 (furnished herewith pursuant
          to Item 7.01)
 99.2       Press Release dated April 12, 2021

© Edgar Online, source Glimpses